Radioembolization with 90yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies - Part 1: Technical and methodologic considerations

Journal of Vascular and Interventional Radiology

Volumn 17, Issue 8, 2006, Pages 1251-1278

  Salem, Riad ^a   Thurston, Kenneth G ^b  

^a Robert H Lurie Comprehensive Cancer ^*  (United States)

^b MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN TC 99M; ETHIODIZED OIL; FLOXURIDINE; MICROSPHERE; YTTRIUM 90; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ARTIFICIAL EMBOLISM; BRACHYTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTERVENTIONAL RADIOLOGY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER METASTASIS; LIVER WEIGHT; LUNG ARTERIOVENOUS SHUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION SAFETY; REVIEW; ANGIOGRAPHY; COMPUTER ASSISTED RADIOTHERAPY; DISEASE MANAGEMENT; LIVER TUMOR; MESENTERY; METASTASIS; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT SELECTION; PRACTICE GUIDELINE; RADIATION DOSE; RADIOGRAPHY; SPLANCHNIC BLOOD FLOW; VASCULARIZATION;

ANGIOGRAPHY; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; DISEASE MANAGEMENT; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; MESENTERY; MICROSPHERES; PATIENT CARE TEAM; PATIENT SELECTION; PRACTICE GUIDELINES; RADIOLOGY, INTERVENTIONAL; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SPLANCHNIC CIRCULATION; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 33747515562     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000233785.75257.9A     Document Type: Review

References (87)

1. TheraSphere Yttrium-90 microspheres [package insert]. Kanata, ON, Canada: MDS Nordion, 2004.
2. Humanitarian Device Exemptions (HDE) Regulations: Questions and Answers; Final Guidance for Industry. Available at http://www.fda.gov/cdrh/ode/guidance/ 1381.html.
3. SIR-Spheres Yttrium-90 microspheres [package insert]. Lane Cove, Australia: Sirtex Medical. 2004.
4. American Cancer Society. Cancer Facts & Figures 2004. Atlanta: American Cancer Society, 2004.
5. Salem R, Hunter R. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: a review. Int J Radiat Oncol Biol Phys (in press).
6. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994; 70:994-999.
7. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40:583-592.
8. Cao X, He N, Sun J, et al. Hepatic radioembolization with yttrium-90 glass microspheres for treatment of primary liver cancer. Chin Med J (Engl) 1999; 112:430-432.
9. Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 2004; 7:431-441.
10. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430.
11. Carr BI. Hepatic arterial 90yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004; 10(2 suppl 1):S107-S110.
12. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000; 41:1673-1681.
13. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127(5 suppl 1): S194-S205.
14. Deleted in proof.
15. Salem R, Lewandowski R, Roberts C, et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004; 15:335-345.
16. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16:1627-1639.
17. Salem R, Thurston KG, Carr BI, et al. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002; 13(suppl): S223-S229.
18. Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of cisplatin versus 90-yttrium microspheres (Therasphere). Psychooncology 2004; 13:73-79.
19. Liu MD, Uaje MB, Al-Ghazi MS, et al. Use of yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. Am Surg 2004; 70:947-953.
20. Messersmith W, Laheru D, Hidalgo M. Recent advances in the pharmacological treatment of colorectal cancer. Expert Opin Investig Drugs 2003; 12:423-434.
21. Mulcahy MF, Benson AB III. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2005; 5:997-1005.
22. Hoff PM. Future directions in the use of antiangiogenic agents in patients with colorectal cancer. Semin Oncol 2004; 31(6 suppl 17):17-21.
23. Sasson AR, Sigurdson ER. Surgical treatment of liver metastases. Semin Oncol 2002; 29:107-118.
24. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12:1711-1720.
25. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology 2001; 48:333-337.
26. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg 2001; 5:294-302.
27. Rubin D, Nutting C, Jones B. Metastatic breast cancer in a 54-year-old woman: integrative treatment with yttrium-90 radioembolization. Integr Cancer Ther 2004; 3:262-267.
28. Wong CY, Qing F, Savin M, et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18f]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 2005; 16:1101-1106.
29. Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 2005; 16:937-945.
30. Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/non- alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol 2004; 18:1089-1104.
31. Kim TK, Jang HJ, Wilson SR. Imaging diagnosis of hepatocellular carcinoma with differentiation from other pathology. Clin Liver Dis 2005; 9:253-279.
32. Alobaidi M, Shirkhoda A. Benign focal liver lesions: discrimination from malignant mimickers. Curr Probl Diagn Radiol 2004; 33:239-253.
33. Lim JH, Choi D, Kim SH, et al. Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol 2002; 179:67-73.
34. Kim YK, Kim CS, Lee YH, et al. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas. AJR Am J Roentgenol 2004; 182:1217-1223.
35. Rhee TK, Larson AC, Prasad PV, et al. Feasibility of blood oxygenation level-dependent MR imaging to monitor hepatic transcatheter arterial embolization in rabbits. J Vasc Interv Radiol 2005; 16:1523-1528.
36. Llovet JM, Vilana R, Bru C, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001; 33:1124-1129.
37. Geschwind JF, Artemov D, Abraham S, et al. Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol 2000; 11:1245-1255.
38. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56:918-928.
39. Rhee TK, Omary RA, Gates V, et al. The effect of catheter-directed ct angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol 2005; 16:1085-1091.
40. Toyoda H, Kumada T, Kiriyama S, et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 2005; 100:1764-1771.
41. Kulik L, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006 (in press).
42. Lewandowski RJ, Thurston KG, Goin JE, et al. 90Y Microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005; 16:1641-1651.
43. Lencioni R, Crocetti L, Cioni D, et al. Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. Invest Radiol 2004; 39:689-697.
44. Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 2004; 45:1892-1897.
45. Wong CY, Salem R, Raman S, et al. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F] FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002; 29:815-820.
46. Jerusalem G, Hustinx R, Beguin Y, et al. Evaluation of therapy for lymphoma. Semin Nucl Med 2005; 35:186-196.
47. Tellez C, Benson AB III, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998; 82:1250-1259.
48. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003; 3:8-24.
49. Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005; 103:1856-1864.
50. Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005; 16:911-935.
51. Chen JH, Chai JW, Huang CL, et al. Proximal arterioportal shunting associated with hepatocellular carcinoma: features revealed by dynamic helical CT. AJR Am J Roentgenol 1999; 172:403-407.
52. Ho S, Lau WY, Leung TW, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 1996; 23:947-952.
53. Mounajjed T, Salem R, Rhee TK, et al. Multi-institutional comparison of 99mTc-MAA lung shunt fraction for transcatheter Y-90 radioembolization. Presented at the Annual Meeting of the Society of Interventional Radiology, 2005. New Orleans, LA.
54. Hung JC, Redfern MG, Mahoney DW, et al. Evaluation of macroaggregated albumin particle sizes for use in pulmonary shunt patient studies. J Am Pharm Assoc (Wash) 2000; 40:46-51.
55. Ho S, Lau WY, Leung TW, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997; 24:293-298.
56. Kim HC, Chung JW, Lee W, et al. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics 2005; 25(suppl 1):S25-S39.
57. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005; 25(suppl 1):S41-S55.
58. Sato KT, Omary RA, Ryu R, et al. Radioembolization with yttrium-90 microspheres: angiographic and technical considerations. Tech Vasc Interv Radiol 2006 (in press).
59. Nakamura H, Hashimoto T, Oi H, et al. Prevention of gastric complications in hepatic arterial chemoembolization: balloon catheter occlusion technique. Acta Radiol 1991; 32:81-82.
60. Song SY, Chung JW, Lim HG, et al. Nonhepatic arteries originating from the hepatic arteries: angiographic analysis in 250 patients. J Vasc Interv Radiol 2006; 17:461-469.
61. Urbach DR, Herron DM, Khajanchee YS, et al. Laparoscopic hepatic artery infusion pump placement. Arch Surg 2001; 136:700-704.
62. Kulik LM, Mulcahy MF, Hunter RD, et al. Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl 2005; 11:1127-1131.
63. Charnsangavej C. Chemoembolization of liver tumors. Sem Invest Radiol 1993; 10:150-160.
64. Fischer L, Thorn M, Neumann JO, et al. The segments of the hepatic veins: is there a spatial correlation to the Couinaud liver segments? Eur J Radiol 2005; 53:245-255.
65. Erbe EM, Day DE. Chemical durability of Y2O3-Al2O3-SiO2 glasses for the in vivo delivery of beta radiation. J Biomed Mater Res 1993; 27:1301-1308.
66. Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004; 60:1552-1563.
67. Murthy R, Kennedy A, Line B, et al. Augmentation of hepatopulmonary shunting following trans-arterial hepatic brachytherapy with Y90 TheraSphere: therapeutic implications. Presented at the Radiological Society of North America, 2002. Chicago, IL.
68. Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006; 29:522-529.
69. Goin JE, Dancey JE, Roberts CA, et al. Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter arterial chemo-embolization versus yttrium-90 glass microspheres. World J Nucl Med 2004; 3:49-56.
70. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 2005; 16:195-203.
71. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005; 16:205-213.
72. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88:78-85.
73. Body Surface Area Calculator. Available at http://www.halls.md/ bodysurface-area/refs.htm.
74. DuBois D, DuBois E. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 1916; 17:863-871.
75. Deutsch E, Huguet F. Perspectives in biological modulation of radiotherapy. Bull Cancer 2005; 92:90-96.
76. Koukourakis MI. Tumour angiogenesis and response to radiotherapy. Anticancer Res 2001; 21(6B):4285-4300.
77. Das U. A radical approach to cancer. Med Sci Monit 2002; 8:RA79-RA92.
78. Hakim TS, Dean GW, Lisbona R. Effect of body posture on spatial distribution of pulmonary blood flow. J Appl Physiol 1988; 64:1160-1170.
79. Kosuda S, Kobayashi H, Kusano S. Change in regional pulmonary perfusion as a result of posture and lung volume assessed using technetium-99m macroaggregated albumin SPET. Eur J Nucl Med 2000; 27:529-535.
80. Beck KC. Regional trapping of microspheres in the lung compares well with regional blood flow. J Appl Physiol 1987; 63:883-889.
81. Berger MJ. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. J Nucl Med 1971: suppl 5:5-23.
82. Snyder W, Ford M, Warner G, et al. Absorbed dose per unit cumulated activity for selected radionuclides and organs. New York: Society of Nuclear Medicine, 1975-1976.
83. Sirtex Medical Training Manual. Lane Cove, Australia: Sirtex Medical, 2005.
84. Gray BN. Use of SIR-Spheres in patients with impaired liver function: safety notice. Lane Cove, Australia: Sirtex Medical, 2003.
85. Yip D, Allen R, Ashton C, et al. Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer. J Gastroenterol Hepatol 2004; 19:347-349.
86. Salem R. Idiosyncratic reactions following Y90 treatment. Chicago: Northwestern Memorial Hospital, 2006.
87. De Ledinghen V, Heresbach D, Fourdan O, et al. Anti-inflammatory drugs and variceal bleeding: a casecontrol study. Gut 1999; 44:270-273.